The other way.

First 31 Last

Share
Profile

Follow
vasilios

3,785 Posts.

359

18/04/20

10:31

Post #: 44114753
Share

Originally posted by Wazza222: ↑

My understanding of Remestemcel-L in the CV context is that it is for use with critically ill patients who have severe respiratory problems and likely already need a ventilator to survive.
The tests Gilead are doing are on severely ill patients (ie one step before critical). If their drug works,and patients walk out of hospital with no further respiratory complications - then suddenly there is no one in further need of critical care and thus our stem cells. This is where Gileads' drug is a threat to MSB - not that they are competing products but that theirs is preventing the disease progressing to the next stage.
There are still plenty of cases out there who are past the severe stage and hopefully MSB is the go to company to treat them. The recent anecdotal reports about remdesivir are premature to promote any success yet although it is one of these same "leaked glimpses" of the Mt Sinai trial that we are hanging out for ourselves.
@notbrad8 Your attempts to discredit the journalist despite his forthright follow up interview on CNBC seem unjustified. He appeared genuine and did not have to "back track" on the story he presented. He was doing his job - presenting some information that had come his way (a scoop or perhaps deliberately leaked).

Expand

The other way.

MSB Price at posting: $2.17 Sentiment: Hold Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

CXO

Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered

PMT

High-grade lithium zone extended at Patriot's Corvette project, drilling grades at 5%

WCN

White Cliff gears up to explore expanded Nunavut Cu-Ag-Au project in Canada

HCH

Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant

RXM

Rex Minerals soars 60% on $390M Indonesian buyout deal from MACH Australia

There are more pages in this discussion • 244 more messages in this thread...

First 31 Last

Add MSB (ASX) to my watchlist

(20min delay)
Last $1.11		Change 0.008(0.68%)		Mkt cap ! $1.270B

Open	High	Low	Value	Volume
$1.13	$1.16	$1.10	$5.613M	5.021M

Buyers (Bids)

No.	Vol.	Price($)
23	70796	$1.11

Sellers (Offers)

Price($)	Vol.	No.
$1.12	47015	15

View Market Depth

No.	Vol.	Price($)
31	113738	1.110
23	148397	1.105
17	195051	1.100
16	358052	1.095
11	96304	1.090

Price($)	Vol.	No.
1.115	10772	3
1.120	119849	17
1.125	183538	12
1.130	83263	9
1.135	106877	9

Last trade - 14.39pm 08/07/2024 (20 minute delay)

MSB (ASX) Chart

The other way.

Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered

High-grade lithium zone extended at Patriot's Corvette project, drilling grades at 5%

White Cliff gears up to explore expanded Nunavut Cu-Ag-Au project in Canada

Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant

Rex Minerals soars 60% on $390M Indonesian buyout deal from MACH Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The other way.

Top Stories

Core Lithium narrowly beats guidance on FY24 spodumene production but 1Y returns still shattered

High-grade lithium zone extended at Patriot's Corvette project, drilling grades at 5%

White Cliff gears up to explore expanded Nunavut Cu-Ag-Au project in Canada

Hot Chili sets up water company as drought racks Chile–but must also build communities a desal plant

Rex Minerals soars 60% on $390M Indonesian buyout deal from MACH Australia

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News